Biagio De Angelis - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Biagio De Angelis

Showing results (61-70 of 65) with videos related to

Pageof 7

Sort By:

You have reached the last page of results.This site can display upto 65 results.

Nature Medicine|January 15, 2025

Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastomaConcetta Quintarelli, Francesca Del Bufalo, Maria Antonietta De Ioris, et al.

Nature Medicine|February 5, 2026

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseasesMarco Becilli, Markus Metzler, Claudia Bracaglia, et al.

Journal for Immunotherapy of Cancer|May 16, 2022

Time to evolve: predicting engineered T cell-associated toxicity with next-generation modelsEmmanuel Donnadieu, Maik Luu, Miriam Alb, et al.

The New England Journal of Medicine|April 5, 2023

GD2-CART01 for Relapsed or Refractory High-Risk NeuroblastomaFrancesca Del Bufalo, Biagio De Angelis, Ignazio Caruana, et al.

Nature Communications|December 15, 2023

MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57<sup>Kip2</sup> targetingSilvia Pomella, Matteo Cassandri, Lucrezia D'Archivio, et al.

Pageof 7

Search research articles

Showing results (61-70 of 65) with videos related to

Sort By:

Pageof 7

You have reached the last page of results.This site can display upto 65 results.

Nature Medicine|January 15, 2025

Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastomaConcetta Quintarelli, Francesca Del Bufalo, Maria Antonietta De Ioris, et al.

Nature Medicine|February 5, 2026

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseasesMarco Becilli, Markus Metzler, Claudia Bracaglia, et al.

Journal for Immunotherapy of Cancer|May 16, 2022

Time to evolve: predicting engineered T cell-associated toxicity with next-generation modelsEmmanuel Donnadieu, Maik Luu, Miriam Alb, et al.

The New England Journal of Medicine|April 5, 2023

GD2-CART01 for Relapsed or Refractory High-Risk NeuroblastomaFrancesca Del Bufalo, Biagio De Angelis, Ignazio Caruana, et al.

Nature Communications|December 15, 2023

MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57<sup>Kip2</sup> targetingSilvia Pomella, Matteo Cassandri, Lucrezia D'Archivio, et al.

Pageof 7